tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million series a investment from third rock ventures. the company has established a robust product engine that leverages advances in dna sequencing and crispr-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. tango therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. these include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. what fuels each of tango’s programs is an increasingly sophisticated ability to util
Company profile
Ticker
TNGX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BCTG Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Tango Therapeutics Sub, Inc. • Tango Securities Corporation ...
TNGX stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
17 Apr 24
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
18 Mar 24
8-K
Results of Operations and Financial Condition
7 Feb 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Tango Therapeutics Reports Third Quarter 2023 Financial Results
8 Nov 23
EFFECT
Notice of effectiveness
12 Sep 23
CORRESP
Correspondence with SEC
7 Sep 23
UPLOAD
Letter from SEC
7 Sep 23
Latest ownership filings
SC 13G/A
Southpoint Capital Advisors LP
8 Apr 24
4
Change in insider ownership
21 Feb 24
144
Notice of proposed sale of securities
21 Feb 24
SC 13G/A
Southpoint Capital Advisors LP
14 Feb 24
SC 13G/A
GILEAD SCIENCES, INC.
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Barbara Weber
8 Feb 24
4
Douglas Barry
8 Feb 24
4
Daniella Beckman
8 Feb 24
4
Adam Crystal
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 61.96 mm | 61.96 mm | 61.96 mm | 61.96 mm | 61.96 mm | 61.96 mm |
Cash burn (monthly) | 2.51 mm | 3.53 mm | 8.54 mm | 9.14 mm | 10.38 mm | 9.90 mm |
Cash used (since last report) | 17.30 mm | 24.36 mm | 58.97 mm | 63.13 mm | 71.65 mm | 68.34 mm |
Cash remaining | 44.65 mm | 37.59 mm | 2.98 mm | -1.17 mm | -9.69 mm | -6.38 mm |
Runway (months of cash) | 17.8 | 10.7 | 0.3 | -0.1 | -0.9 | -0.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 103 |
Opened positions | 23 |
Closed positions | 11 |
Increased positions | 34 |
Reduced positions | 25 |
13F shares | Current |
---|---|
Total value | 981.14 bn |
Total shares | 125.68 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TRV GP Iv | 19.36 mm | $218.04 bn |
Third Rock Ventures IV | 19.36 mm | $197.51 mm |
FMR | 11.65 mm | $131.13 bn |
EcoR1 Capital | 8.72 mm | $98.21 bn |
Boxer Capital | 7.12 mm | $80.21 bn |
BCTG | 7.12 mm | $53.50 mm |
Nextech Invest | 5.53 mm | $62.31 bn |
Nextech Crossover I GP S.a r.l. | 5.53 mm | $41.56 mm |
Southpoint Capital Advisors | 5.28 mm | $59.42 bn |
GILD Gilead Sciences | 4.85 mm | $49.52 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Third Rock Ventures IV | Common Stock | Sell | Dispose S | No | No | 12 | 162,500 | 1.95 mm | 19,201,475 |
7 Feb 24 | Weber Barbara | Common Stock | Sell | Dispose S | No | No | 12.6198 | 4,457 | 56.25 k | 1,535,167 |
7 Feb 24 | Douglas Barry | Common Stock | Sell | Dispose S | No | No | 12.6198 | 1,354 | 17.09 k | 43,981 |
7 Feb 24 | Beckman Daniella | Common Stock | Sell | Dispose S | No | No | 12.6198 | 1,817 | 22.93 k | 132,397 |
7 Feb 24 | Adam Crystal | Common Stock | Sell | Dispose S | No | No | 12.6198 | 4,083 | 51.53 k | 119,478 |
6 Feb 24 | Weber Barbara | Common Stock | Sell | Dispose S | No | No | 12.5626 | 4,681 | 58.81 k | 1,539,624 |
6 Feb 24 | Douglas Barry | Common Stock | Sell | Dispose S | No | No | 12.5626 | 1,422 | 17.86 k | 45,335 |
6 Feb 24 | Beckman Daniella | Common Stock | Sell | Dispose S | No | No | 12.5626 | 1,908 | 23.97 k | 134,214 |
6 Feb 24 | Adam Crystal | Common Stock | Sell | Dispose S | No | No | 12.5626 | 4,288 | 53.87 k | 123,561 |
News
Cantor Fitzgerald Initiates Coverage On Tango Therapeutics with Overweight Rating
4 Apr 24
Recap: Tango Therapeutics Q4 Earnings
18 Mar 24
Tango Therapeutics Q4 GAAP EPS $(0.32) Misses $(0.28) Estimate, Sales $5.43M Miss $8.24M Estimate
18 Mar 24
Piper Sandler Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $18
12 Feb 24
Press releases
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
Tango Therapeutics to Participate in Upcoming Investor Conferences
6 Mar 24
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
5 Mar 24
Pancreatic Cancer Treatments Poised for Major Advances in 2024
7 Feb 24
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
31 Jan 24